Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
about
Pathophysiological Significance of Store-Operated Calcium Entry in Megakaryocyte Function: Opening New Paths for Understanding the Role of Calcium in ThrombopoiesisPrimary autoimmune myelofibrosis with severe thrombocytopenia mimicking immune thrombocytopenia: A case report.2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and TFibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis.Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis.Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis.Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A ReviewMolecular Mechanism of Mutant CALR-Mediated Transformation.A Genetic Screen Reveals an Unexpected Role for Yorkie Signaling in JAK/STAT-Dependent Hematopoietic Malignancies in Drosophila melanogaster.Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations.Can pegylated interferon improve the outcome of polycythemia vera patients?Which clinical significance has automatic detection of very low levels of nucleated red blood cells in the peripheral blood?Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population.Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.Essential thrombocythemia treatment algorithm 2018.Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases.Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis.Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015.Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis.Recent advances in the diagnosis and management of primary myelofibrosis.
P2860
Q28069839-FB56D272-139C-4E0E-B22B-14949452997FQ33438592-589C590C-6E88-411F-BDBF-5FB36A50FFEBQ33572605-359BD2AA-2FDA-41A7-800E-1F93CC755E8DQ36308248-9F2756B5-9A4A-4651-8B30-FBFF93BF1247Q37683345-6E1E217D-E670-4489-B365-8695F824CF4CQ38798560-73F0EAE2-CB71-47AA-A821-0F3CE4EC8652Q38938526-5C59D09D-B082-4711-B9FB-BDC441BBCB6FQ38984558-C967107D-CC38-42E4-AAED-EB3826B4EFEEQ40219231-3E93673B-8566-45FD-B179-FB3B9411C111Q41380766-484746C7-BC98-4C18-9DD9-17F9CC5AC420Q42292798-98B4B1CF-8565-4CD9-8F9E-642A07B46A1DQ42330314-4468A02F-E7D2-4BD5-B3A9-4FC8CFEA4EF3Q42576698-650F8621-D63D-4374-AFA2-B0902E897BFCQ46886345-3D73BF60-8453-4108-9E8D-88EA16B847E9Q47102771-75AB78A1-4EC2-4F16-9F23-D244CADC4FC4Q47139100-8125096B-B30B-46CD-957E-426A50417803Q47209528-2180C128-6433-4DA3-9B3B-A9671B73F460Q47565721-0B5F4A93-E893-4160-90D9-ACBB85E116FEQ48186643-249A20A1-B427-48F1-BC69-6DC6EB2D7A68Q48197162-9D134816-2BC3-414F-9F5A-46670DDA2ACFQ48311474-8FABEE4B-F471-4DCD-9427-063BB8D6ACD4Q50327748-A71742D5-6AB8-4FDE-AF7B-981FDCEECB31Q50871377-D5A64398-751F-4651-B5EF-8DA1C8742B7CQ54980872-9F204981-E229-4DA5-88CF-46754AF8C3B2
P2860
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
@en
type
label
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
@en
prefLabel
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
@en
P2860
P356
P1476
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
@en
P2860
P356
10.1002/AJH.24221
P577
2015-10-22T00:00:00Z